1
|
Swinkels M, Atiq F, Bürgisser PE, Moort I, Meijer K, Eikenboom J, Fijnvandraat K, Galen KPM, Meris J, Schols SEM, Bom JG, Cnossen MH, Voorberg J, Leebeek FWG, Bierings R, Jansen AJG, Fijnvandraat K, Coppens M, Meris J, Nieuwenhuizen L, Meijer K, Tamminga RYJ, Ypma PF, Eikenboom HCJ, Bom JG, Smiers FJW, Granzen B, Moenen F, Brons P, Schols SEM, Leebeek FWG, Cnossen MH, Atiq F, Kwawegen CB, Galen KPM. Platelet degranulation and bleeding phenotype in a large cohort of Von Willebrand disease patients. Br J Haematol 2022; 197:497-501. [PMID: 36165954 PMCID: PMC9314899 DOI: 10.1111/bjh.18145] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Revised: 02/24/2022] [Accepted: 03/02/2022] [Indexed: 11/30/2022]
Abstract
Von Willebrand disease (VWD) is a bleeding disorder caused by quantitative (type 1 or 3) or qualitative (type 2A/2B/2M/2N) defects of circulating von Willebrand factor (VWF). Circulating VWF levels not always fully explain bleeding phenotypes, suggesting a role for alternative factors, like platelets. Here, we investigated platelet factor 4 (PF4) in a large cohort of patients with VWD. PF4 levels were lower in type 2B and current bleeding phenotype was significantly associated with higher PF4 levels, particularly in type 1 VWD. Based on our findings we speculate that platelet degranulation and cargo release may play a role across VWD subtypes.
Collapse
Affiliation(s)
- Maurice Swinkels
- Department of Hematology Erasmus University Medical Center Rotterdam The Netherlands
| | - Ferdows Atiq
- Department of Hematology Erasmus University Medical Center Rotterdam The Netherlands
| | - Petra E. Bürgisser
- Department of Hematology Erasmus University Medical Center Rotterdam The Netherlands
| | - Iris Moort
- Department of Hematology Erasmus University Medical Center Rotterdam The Netherlands
| | - Karina Meijer
- Department of Hematology, University Medical Center Groningen University of Groningen Groningen The Netherlands
| | - Jeroen Eikenboom
- Department of Internal Medicine, Division of Thrombosis and Hemostasis Leiden University Medical Center Leiden The Netherlands
- Einthoven Laboratory for Vascular and Regenerative Medicine Leiden University Medical Center Leiden The Netherlands
| | - Karin Fijnvandraat
- Department of Pediatric Hematology Emma Children's Hospital‐Academic Medical Centre Amsterdam The Netherlands
| | - Karin P. M. Galen
- Van Creveldkliniek, University Medical Center Utrecht Utrecht University Utrecht The Netherlands
| | - Joke Meris
- Netherlands Hemophilia Society Leiden The Netherlands
| | - Saskia E. M. Schols
- Department of Hematology Radboud University Medical Center and Hemophilia Treatment Center Nijmegen‐Eindhoven‐Maastricht Nijmegen The Netherlands
| | - Johanna G. Bom
- Department of Clinical Epidemiology Leiden University Medical Center Leiden The Netherlands
| | - Marjon H. Cnossen
- Department of Pediatric Hematology Erasmus University Medical Center‐Sophia Children's Hospital Rotterdam The Netherlands
| | - Jan Voorberg
- Department of Molecular Hematology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Center University of Amsterdam Amsterdam The Netherlands
- Department of Experimental Vascular Medicine, Amsterdam University Medical Center University of Amsterdam Amsterdam The Netherlands
| | - Frank W. G. Leebeek
- Department of Hematology Erasmus University Medical Center Rotterdam The Netherlands
| | - Ruben Bierings
- Department of Hematology Erasmus University Medical Center Rotterdam The Netherlands
| | - A. J. Gerard Jansen
- Department of Hematology Erasmus University Medical Center Rotterdam The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Houwing ME, de Pagter PJ, van Beers EJ, Biemond BJ, Rettenbacher E, Rijneveld AW, Schols EM, Philipsen JNJ, Tamminga RYJ, van Draat KF, Nur E, Cnossen MH. Sickle cell disease: Clinical presentation and management of a global health challenge. Blood Rev 2019; 37:100580. [PMID: 31128863 DOI: 10.1016/j.blre.2019.05.004] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2018] [Revised: 05/17/2019] [Accepted: 05/17/2019] [Indexed: 01/12/2023]
Abstract
Sickle cell disease is an autosomal recessive, multisystem disorder, characterised by chronic haemolytic anaemia, painful episodes of vaso-occlusion, progressive organ failure and a reduced life expectancy. Sickle cell disease is the most common monogenetic disease, with millions affected worldwide. In well-resourced countries, comprehensive care programs have increased life expectancy of sickle cell disease patients, with almost all infants surviving into adulthood. Therapeutic options for sickle cell disease patients are however, still scarce. Predictors of sickle cell disease severity and a better understanding of pathophysiology and (epi)genetic modifiers are warranted and could lead to more precise management and treatment. This review provides an extensive summary of the pathophysiology and management of sickle cell disease and encompasses the characteristics, complications and current and future treatment options of the disease.
Collapse
Affiliation(s)
- M E Houwing
- Department of Paediatric Haematology, Erasmus University Medical Center - Sophia Children's Hospital, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands.
| | - P J de Pagter
- Department of Paediatric Haematology, Erasmus University Medical Center - Sophia Children's Hospital, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands.
| | - E J van Beers
- Department of Internal Medicine and Dermatology, Van Creveldkliniek, University Medical Center Utrecht, Internal mail no C.01.412, 3508, GA, Utrecht, the Netherlands.
| | - B J Biemond
- Department of Internal Medicine and Clinical Haematology, Amsterdam University Medical Centers, Meibergdreef 9, 1105, AZ, Amsterdam, the Netherlands.
| | - E Rettenbacher
- Department of Paediatric Haematology, Radboud University Medical Center - Amalia Children's Hospital, Geert Grooteplein Zuid 10, 6500, HB, Nijmegen, the Netherlands.
| | - A W Rijneveld
- Department of Haematology, Erasmus University Medical Center, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands.
| | - E M Schols
- Department of Haematology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525, GA, Nijmegen, the Netherlands.
| | - J N J Philipsen
- Department of Cell Biology, Erasmus University Medical Center, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands.
| | - R Y J Tamminga
- Department of Paediatric Oncology and Haematology, University Medical Center Groningen - Beatrix Children's Hospital, Postbus 30001, 9700, RB, Groningen, the Netherlands..
| | - K Fijn van Draat
- Department of Paediatric Haematology, Amsterdam University Medical Centers - Emma Children's Hospital, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands; Department of Plasma Proteins, Sanquin Research, the Netherlands.
| | - E Nur
- Department of Internal Medicine and Clinical Haematology, Amsterdam University Medical Centers, Meibergdreef 9, 1105, AZ, Amsterdam, the Netherlands.
| | - M H Cnossen
- Department of Paediatric Haematology, Erasmus University Medical Center - Sophia Children's Hospital, Wytemaweg 80, 3015, CN, Rotterdam, the Netherlands.
| |
Collapse
|
3
|
Maagdenberg H, Bierings MB, van Ommen CH, van der Meer FJM, Appel IM, Tamminga RYJ, le Cessie S, Swen JJ, van der Straaten T, de Boer A, Maitland-van der Zee AH. The pediatric acenocoumarol dosing algorithm: the Children Anticoagulation and Pharmacogenetics Study. J Thromb Haemost 2018; 16:1732-1742. [PMID: 29935043 DOI: 10.1111/jth.14211] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Indexed: 12/18/2022]
Abstract
Essentials A pediatric pharmacogenetic dosing algorithm for acenocoumarol has not yet been developed. We conducted a multicenter retrospective follow-up study in children in the Netherlands. Body surface area and indication explained 45.0% of the variability in dose requirement. Adding the genotypes of VKORC1, CYP2C9 and CYP2C18 to the algorithm increased this to 61.8%. SUMMARY Background The large variability in dose requirement of vitamin K antagonists is well known. For warfarin, pediatric dosing algorithms have been developed to predict the correct dose for a patient; however, this is not the case for acenocoumarol. Objectives To develop dosing algorithms for pediatric patients receiving acenocoumarol with and without genetic information. Methods The Children Anticoagulation and Pharmacogenetics Study was designed as a multicenter retrospective follow-up study in Dutch anticoagulation clinics and children's hospitals. Pediatric patients who used acenocoumarol between 1995 and 2014 were selected for inclusion. Clinical information and saliva samples for genotyping of the genes encoding cytochrome P450 (CYP) 2C9, vitamin K epoxide reductase complex subunit 1 (VKORC1), CYP4F2, CYP2C18 and CYP3A4 were collected. Linear regression was used to analyze their association with the log mean stable dose. A stable period was defined as three or more consecutive International Normalized Ratio measurements within the therapeutic range over a period of ≥ 3 weeks. Results In total, 175 patients were included in the study, of whom 86 had a stable period and no missing clinical information (clinical cohort; median age 8.9 years, and 49% female). For 80 of these 86 patients, genetic information was also available (genetic cohort). The clinical algorithm, containing body surface area and indication, explained 45.0% of the variability in dose requirement of acenocoumarol. After addition of the VKORC1, CYP2C9, and CYP2C18 genotypes to the algorithm, this increased to 61.8%. Conclusions These findings show that clinical factors had the largest impact on the required dose of acenocoumarol in pediatric patients. Nevertheless, genetic factors, and especially VKORC1, also explained a significant part of the variability.
Collapse
Affiliation(s)
- H Maagdenberg
- Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
| | - M B Bierings
- Department of Pediatric Hematology and Stem Cell Transplantation, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands
| | - C H van Ommen
- Department of Pediatric Oncology/Hematology, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - F J M van der Meer
- Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands
| | - I M Appel
- Department of Pediatric Oncology/Hematology, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - R Y J Tamminga
- Department of Pediatric Hematology, University Medical Center Groningen, Groningen, the Netherlands
| | - S le Cessie
- Department of Medical Statistics, Leiden University Medical Center, Leiden, the Netherlands
- Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands
| | - J J Swen
- Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands
| | - T van der Straaten
- Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands
| | - A de Boer
- Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
| | - A H Maitland-van der Zee
- Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
- Department of Respiratory Medicine, Amsterdam Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| |
Collapse
|
4
|
Maagdenberg H, Bierings MB, van Ommen CH, van der Meer FJM, Appel IM, Tamminga RYJ, de Boer A, Maitland-van der Zee AH. Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort. J Thromb Haemost 2018; 16:116-124. [PMID: 29108090 DOI: 10.1111/jth.13897] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2017] [Indexed: 01/31/2023]
Abstract
Essentials The knowledge of quality and safety of acenocoumarol and phenprocoumon use in children is limited. We used data from a multicenter retrospective follow-up study in children in the Netherlands. The quality of anticoagulation control in the first month of use was low, but improved thereafter. No thromboembolic events occurred, however bleeding events occurred in 1-3 out of 10 patients. SUMMARY Background The use of vitamin-K antagonists in pediatric patients is rare and information on the quality and safety of treatment with acenocoumarol and phenprocoumon is limited. Objectives To assess the quality, safety and effectiveness during the first year of acenocoumarol and phenprocoumon treatment in pediatric patients in the Netherlands. Methods The Children Anticoagulation and Pharmacogenetics Study (CAPS) was designed as a multicenter retrospective follow-up study. Patients who used acenocoumarol or phenprocoumon at an age of ≤ 18 years, were selected from four pediatric hospitals and one anticoagulation clinic in the Netherlands. The quality of treatment was assessed by calculating the percentage of time in therapeutic INR range (TTR) for the first month and for every 3 months of use during the first year of treatment. Effectiveness and safety were assessed by the number of thromboembolic and bleeding events. Results In total, 213 patients participated, of whom 187 (155 acenocoumarol; 32 phenprocoumon) were included in this analysis. The mean TTR was 47.0% and 51.4% in the first month of use for acenocoumarol and phenprocoumon, respectively. After the first 3 months the mean TTR for both VKAs was above 64%. In 14.6% (acenocoumarol) and 31.3% (phenprocoumon) of the patients a bleeding event occurred during the first year of treatment; no thromboembolic events were reported. Conclusions The quality of anticoagulation treatment was low during the first month of use and leaves room for improvement. After the first month it increased to an acceptable level. However, bleeding events occurred frequently during the first year.
Collapse
Affiliation(s)
- H Maagdenberg
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands
| | - M B Bierings
- Department of Pediatric Hematology and Stem Cell Transplantation, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands
| | - C H van Ommen
- Department of Pediatric Oncology/Hematology, Erasmus MC/Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - F J M van der Meer
- Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands
| | - I M Appel
- Department of Pediatric Oncology/Hematology, Erasmus MC/Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - R Y J Tamminga
- Department of Pediatric Hematology, University Medical Center Groningen, Groningen, the Netherlands
| | - A de Boer
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands
| | - A H Maitland-van der Zee
- Department of Respiratory Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| |
Collapse
|
5
|
Rosman CWK, Broens PMA, Trzpis M, Tamminga RYJ. A long-term follow-up study of subtotal splenectomy in children with hereditary spherocytosis. Pediatr Blood Cancer 2017; 64. [PMID: 28417547 DOI: 10.1002/pbc.26592] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2016] [Accepted: 03/09/2017] [Indexed: 01/09/2023]
Abstract
BACKGROUND Hereditary spherocytosis (HS) is a heterogeneous hemolytic anemia treated with splenectomy in patients suffering from severe or moderate disease. Total splenectomy, however, renders patients vulnerable to overwhelming postsplenectomy infection despite preventive measures. Although subtotal splenectomy has been advocated as an alternative to total splenectomy, long-term follow-up data are scarce. We investigated how often hematologic recurrences requiring secondary total splenectomy occurred. PROCEDURE With a follow-up of at least 5 years, we analyzed the data of 12 patients, aged 11 years maximum (median 6.5 years), who had undergone intended subtotal splenectomy, and 9 patients (median age 11.9 years), who had undergone total splenectomy. We compared their hematologic results and searched for factors associated with secondary spleen surgery. RESULTS Hemolysis was reduced after subtotal splenectomy and absent after total splenectomy. Subtotal splenectomy was not successful in three children because no functional splenic remnant remained after 6 months (one conversion at surgery; one necrosis of splenic remnant; one early secondary splenectomy). Four children required secondary splenectomy after a median of 5 years for hematologic recurrence. In the remaining five patients, a functional splenic remnant was present for at least 5.5 years. The median time to secondary total splenectomy after intended subtotal splenectomy was 5.2 years. In all patients requiring secondary total splenectomy, increased reticulocyte levels within 2 years indicated hematologic recurrence. CONCLUSIONS Subtotal splenectomy can be an alternative for total splenectomy in young patients with HS. It allows for hematologic improvement and may preserve splenic immune function for as many as 5 years.
Collapse
Affiliation(s)
- C W K Rosman
- Division of Pediatric Oncology and Hematology, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - P M A Broens
- Division of Pediatric Surgery, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.,Anorectal Physiology Laboratory, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - M Trzpis
- Anorectal Physiology Laboratory, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - R Y J Tamminga
- Division of Pediatric Oncology and Hematology, Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| |
Collapse
|
6
|
Ludikhuize L, Jansen ME, Hooimeijer HL, de Bont ESJM, Tamminga RYJ. Feasibility of video consultations in case of acute complications in children with haemophilia. Haemophilia 2016; 22:e567-e570. [PMID: 27761970 DOI: 10.1111/hae.13109] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/02/2016] [Indexed: 10/20/2022]
Affiliation(s)
- L Ludikhuize
- Division of Pediatric Hematology, Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - M E Jansen
- Division of Pediatric Hematology, Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - H L Hooimeijer
- Division of Pediatric Hematology, Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - E S J M de Bont
- Division of Pediatric Hematology, Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - R Y J Tamminga
- Division of Pediatric Hematology, Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| |
Collapse
|
7
|
Fransen van de Putte DE, Frankhuizen WS, Vijfhuizen L, Groenewegen L, Tamminga RYJ, Bouman K, van Essen AJ, Gijsbers ACJ, Ruivenkamp CAL, Boon EMJ. Risk of erroneous results in carrier testing for haemophilia A without prior DNA analysis in male index patients. Haemophilia 2015; 21:e237-e239. [PMID: 25655912 DOI: 10.1111/hae.12648] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/09/2015] [Indexed: 06/04/2023]
Affiliation(s)
| | - W S Frankhuizen
- Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - L Vijfhuizen
- Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - L Groenewegen
- Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - R Y J Tamminga
- University Medical Center Groningen, Beatrix Children's Hospital, University of Groningen, Groningen, The Netherlands
| | - K Bouman
- Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - A J van Essen
- Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - A C J Gijsbers
- Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - C A L Ruivenkamp
- Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| | - E M J Boon
- Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
| |
Collapse
|
8
|
Lock J, Raat H, Duncan N, Shapiro A, Beijlevelt M, Peters M, Tamminga RYJ, Leebeek FWG, Moll HA, Cnossen MH. Adherence to treatment in a Western European paediatric population with haemophilia: reliability and validity of the VERITAS-Pro scale. Haemophilia 2014; 20:616-23. [DOI: 10.1111/hae.12463] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/22/2014] [Indexed: 11/29/2022]
Affiliation(s)
- J. Lock
- Department of Paediatric Haematology; Erasmus MC - Sophia Children's Hospital; Rotterdam Netherlands
| | - H. Raat
- Department of Public Health; Erasmus MC, University Medical Centre Rotterdam; Rotterdam Netherlands
| | - N. Duncan
- Department of Haematology; Indiana Haemophilia and Thrombosis Centre; Indianapolis IN USA
| | - A. Shapiro
- Department of Haematology; Indiana Haemophilia and Thrombosis Centre; Indianapolis IN USA
| | - M. Beijlevelt
- Department of Paediatric Haematology; Academic Medical Centre Amsterdam; Amsterdam Netherlands
| | - M. Peters
- Department of Paediatric Haematology; Academic Medical Centre Amsterdam; Amsterdam Netherlands
| | - R. Y. J. Tamminga
- Department of Paediatric Haematology; University Medical Centre Groningen; Groningen Netherlands
| | - F. W. G. Leebeek
- Department of Haematology; Erasmus MC, University Medical Centre Rotterdam; Rotterdam Netherlands
| | - H. A. Moll
- Department of General Paediatrics; Erasmus MC - Sophia Children's Hospital; Rotterdam Netherlands
| | - M. H. Cnossen
- Department of Paediatric Haematology; Erasmus MC - Sophia Children's Hospital; Rotterdam Netherlands
| |
Collapse
|
9
|
Lock J, Raat H, Peters M, Tamminga RYJ, Leebeek FWG, Moll HA, Cnossen MH. Reliability and validity of a novel Haemophilia-specific Self-Efficacy Scale. Haemophilia 2014; 20:e267-74. [DOI: 10.1111/hae.12435] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/09/2014] [Indexed: 11/30/2022]
Affiliation(s)
- J. Lock
- Department of Paediatric Haematology; Erasmus MC - Sophia Children's Hospital; Rotterdam The Netherlands
| | - H. Raat
- Department of Public Health; Erasmus MC, University Medical Centre Rotterdam; Rotterdam The Netherlands
| | - M. Peters
- Department of Paediatric Haematology; Academic Medical Centre Amsterdam; Amsterdam The Netherlands
| | - R. Y. J. Tamminga
- Department of Paediatric Haematology; University Medical Centre Groningen; Groningen The Netherlands
| | - F. W. G. Leebeek
- Department of Haematology; Erasmus MC, University Medical Centre Rotterdam; Rotterdam The Netherlands
| | - H. A. Moll
- Department of General Paediatrics; Erasmus MC - Sophia Children's Hospital; Rotterdam The Netherlands
| | - M. H. Cnossen
- Department of Paediatric Haematology; Erasmus MC - Sophia Children's Hospital; Rotterdam The Netherlands
| |
Collapse
|
10
|
Affiliation(s)
- R Y J Tamminga
- Department of Pediatrics, Beatrix Children's Hospital, University Medical Centre Groningen, University of Groningen, The Netherlands.
| | | | | | | |
Collapse
|
11
|
Meijer K, Bouman K, Sollie KM, Tamminga RYJ, van der Meer J. [Management of pregnancy and childbirth in carriers of haemophilia]. Ned Tijdschr Geneeskd 2008; 152:1249-1253. [PMID: 18590055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
3 pregnant women, aged 27, 33 and 31 years respectively, were carriers of haemophilia A. The first patient had a caesarean section without prior measurement or substitution of factor VIII. She gave birth to a healthy boy, but developed severe diffuse abdominal bleeding after a few hours. The second patient had a normal level of factor VIII, and lived 100 km away from the nearest haemophilia treatment centre. Ultrasound investigation revealed a female foetus. She gave birth in the local hospital. The third patient was pregnant with a male foetus, but refused further prenatal investigation. Contrary to medical advice she gave birth at home. For carriers of haemophilia, there are several options for prenatal diagnosis and managing labour and delivery. Early referral is advised and the need for adequate counselling is explained. It is important to have an experienced haemophilia treatment centre nearby, where haematologists, gynaecologists, geneticists and paediatricians cooperate in caring for pregnant carriers of haemophilia.
Collapse
Affiliation(s)
- K Meijer
- Hemofiliebehandelcentrum, Universitair Medisch Centrum Groningen, Postbus 30.001, 9700 RB Groningen.
| | | | | | | | | |
Collapse
|
12
|
van Vliet MJ, Veeken H, Hart W, Tamminga RYJ. [Clinical reasoning and decision-making in practice. A young boy with fever, pancytopenia and an enlarged spleen]. Ned Tijdschr Geneeskd 2006; 150:1662-8. [PMID: 16922351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
A 5-year-old boy presented with fever and fatigue after a holiday in northern Italy. On physical examination a marked splenomegaly was found. Laboratory investigations showed a pancytopenia as well as several markers suggesting an autoimmune disease. The splenomegaly and pancytopenia continued to progress despite treatment with prednisolone and intravenous immunoglobulins. One and a half years after presentation, the spleen had grown to such an extent that it was causing mechanical problems. Splenectomy was performed for diagnostic and therapeutic purposes. Histological investigation of the spleen showed amastigotes of Leishmania. PCR confirmed the diagnosis visceral leishmaniasis. Leishmaniasis is too often considered to be a tropical disease only. In recent years it has frequently been seen in southern European countries around the Mediterranean Sea.
Collapse
Affiliation(s)
- M J van Vliet
- Universitair Medisch Centrum Groningen, Beatrix Kinderkliniek, Postbus 30.001, 9700 RB Groningen
| | | | | | | |
Collapse
|
13
|
Veneman NGP, Waalkens HJ, Tamminga RYJ. [Anaemia in adopted children, not always iron deficiency]. Ned Tijdschr Geneeskd 2006; 150:1369-72. [PMID: 16841583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
Anaemia was diagnosed in four adopted children during a standard screening examination 1-4 weeks after arrival. Further investigation revealed a number of causes which could then be specifically treated. The children were a girl aged 14 months from China with iron-deficiency anaemia, a boy aged 16 months from Nigeria with sickle cell anaemia, a girl aged 5 from Haiti who had alpha-thalassaemia, and a boy aged 7 from Brazil with spherocytosis. Iron deficiency is the most common cause of anaemia in childhood. However, in adopted children from sub-tropical areas other causes of anaemia like haemoglobinopathies or erythrocyte membrane defects should be borne in mind, particularly as a history of disease and family history are often lacking. Additional investigations may be necessary. An incorrect diagnosis of iron deficiency may result in ongoing and unjustified iron supplementation leading to harmful iron accumulation in thalassaemia and a delay in the correct treatment in sickle cell anemia or spherocytosis which could carry considerable risk.
Collapse
MESH Headings
- Adoption/ethnology
- Anemia/epidemiology
- Anemia/ethnology
- Anemia/etiology
- Anemia, Iron-Deficiency/complications
- Anemia, Iron-Deficiency/diagnosis
- Anemia, Iron-Deficiency/epidemiology
- Anemia, Iron-Deficiency/therapy
- Anemia, Sickle Cell/complications
- Anemia, Sickle Cell/diagnosis
- Anemia, Sickle Cell/epidemiology
- Anemia, Sickle Cell/therapy
- Brazil/ethnology
- Child
- Child, Preschool
- China/ethnology
- Diagnosis, Differential
- Female
- Haiti/ethnology
- Humans
- Infant
- Male
- Mass Screening
- Nigeria/ethnology
- Spherocytosis, Hereditary/complications
- Spherocytosis, Hereditary/diagnosis
- Spherocytosis, Hereditary/epidemiology
- Spherocytosis, Hereditary/therapy
- alpha-Thalassemia/complications
- alpha-Thalassemia/diagnosis
- alpha-Thalassemia/epidemiology
- alpha-Thalassemia/therapy
Collapse
Affiliation(s)
- N G P Veneman
- Martini Ziekenhuis, afd Kindergeneeskunde, Groningen
| | | | | |
Collapse
|
14
|
van Daalen STH, van Dijken PJ, Tamminga RYJ, Brons PPT. [Rituximab instead of splenectomy in 4 children with chronic or refractory autoimmune haemolytic anaemia]. Ned Tijdschr Geneeskd 2005; 149:2350-4. [PMID: 16261716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
4 children, a boy aged 10 years and 3 girls aged 3, 3, and 16 years, suffering from chronic or refractory autoimmune haemolytic anaemia (AIHA), who were dependent on high doses of steroids and were refractory to immunosuppressants, were treated with rituximab at a dose of 375 mg/m2 once a week for 3 or 4 weeks as an alternative to splenectomy. Rituximab is a monoclonal anti-CD20 antibody that prevents the production ofautoantibodies by selective destruction of B-lymphocytes. Haemoglobin levels increased and the parameters of chronic haemolysis (reticulocyte count, lactate dehydrogenase activity, bilirubin concentration) decreased to normal values. 3 patients were taken off corticosteroids completely; 1 of these was also no longer dependent on blood transfusions. Circulating B-lymphocytes were absent for 6 to 15 months after the treatment and the rituximab was well-tolerated. During the treatment, immunoglobulins were substituted and infectious complications were not seen. Rituximab was valuable in the treatment of chronic or refractory AIHA and eliminated the need for splenectomy. 1 patient did not respond to rituximab.
Collapse
Affiliation(s)
- S T H van Daalen
- Universitair Medisch Centrum St Radboud, afd. Kinderhematologieoncologie, Nijmegen
| | | | | | | |
Collapse
|
15
|
Abstract
Treatment of Hodgkin disease (HD) in ataxia telangiectasia (AT) patients is hampered by hypersensitivity to radiation and chemotherapy. Most patients die, due to toxicity or, rarely, to progressive disease. The authors report on a 9-year-old girl with stage IIA HD and AT She was treated with a tailored combined modality approach. No unacceptable toxicity was found, but the girl died of a relapse outside the irradiation field. In comparison with fibroblasts of non-AT patients, the fibroblasts of the patient were 3 times as sensitive for radiotherapy but just 1.2 times as sensitive for doxorubicin. A good correlation was shown between in vitro radio- and chemosensitivity testing and the observed clinical toxicity. The authors suggest, therefore, treating AT patients as much as possible according to standard protocols by adjusting the radiotherapy delivery and the chemotherapy regimen to individual doses derived from in vitro radio- and chemosensitivity testing.
Collapse
Affiliation(s)
- R Y J Tamminga
- Department of Pediatrics, University Hospital Groningen, Beatrix Children's Hospital, The Netherlands.
| | | | | | | |
Collapse
|